Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  MART-1 antigen
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 35 for your search:
Start Over
Vaccine Therapy and/or Sargramostim in Treating Patients With Locally Advanced or Metastatic Melanoma
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000067568, U10CA021115, ECOG-4697, SWOG-E4697, E4697, NCT00005034
Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: 9018, UCCRC-9018, UCCRC-8381, NCI-G97-1162, NCT00002952
Vaccine Therapy in Treating Patients With Stage IV Cutaneous Melanoma
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: ERLANGEN-DERMA-ER-DC-06, CDR0000343699, EU-20317, NCT00074230
Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: 990158, 99-C-0158, NCI-99-C-0158, NCI-T99-0078, T99-0078, NCT00019942, NCT00001832
Vaccine Therapy in Treating Patients With Metastatic Melanoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: CDR0000067391, NCI-99-C-0159, NCI-T99-0079, T99-0079, NCT00019994
Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000069220 (10M-01-1), LAC-USC-10M011, LAC-USC-IRB-013030, NCI-5506, 5506, NCT00031733
Peptide Vaccination for Patients at High Risk for Recurrent Melanoma
Phase: Phase II
Type: Treatment
Status: Closed
Age: 16 and over
Sponsor: NCI
Protocol IDs: 030172, 03-C-0172, NCI-03-C-0172, NCI-6211, 6211, NCT00062218, NCT00059475
Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: CDR0000365467, P30CA076292, P30CA014089, MCC-15241, MDX010-16, NCI-6446, CA184-016, 6446, LAC-USC-10M036, NCT00084656
Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02618, LAC-USC-042011, NCI-6618, LAC-USC-0A1033, CDR0000378033, 10M-03-8, 6618, LAC-USC-10M038, NCT00089063
Vaccine Therapy in Treating Patients With Metastatic Melanoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI, Other
Protocol IDs: 10M-03-1, LAC-USC-10M-03-1, NCI-6262, LAC-USC-033307, CDR0000480137, NCI-2009-00050, 6262, NCT00334776
Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02580, UCCRC-10-324-B, CDR0000696233, 10-324-B, 8445, P30CA014599, N01CM00071, NCT01307618
Phase I Study of MART-1 Human Melanoma Peptide Vaccine in Metastatic Melanoma (Summary Last Modified 01/2000)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-95-C-0071C, NCI-T94-0178N, T94-0178
Phase I Study of Immunization with Adenovirus Encoding the MART-1 Melanoma Antigen for Refractory Metastatic Melanoma (Summary Last Modified 12/1999)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-95-C-0079D, NCI-T94-0195N, T94-0195
Phase I Study of IL-12 Administered with a MART-1 Peptide Vaccine in Patients with Refractory Metastatic Melanoma (Summary Last Modified 11/1999)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-95-C-0143B, NCI-T95-0039N, T95-0039
Phase I Study of Vaccination with MART-1 Antigen in HLA-A2-Positive Patients with Resectable Stage IIB, III, or IV Melanoma (Summary Last Modified 11/1999)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: LAC-USC-10M954, NCI-T95-0069D, T95-0069
Phase I/Ib Study of Tyrosinase/gp100/MART-1 Antigen Peptide Pulsed Dendritic Cell Vaccine for Metastatic Melanoma (Summary Last Modified 01/2000)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: LAC-USC-10M961, NCI-T96-0072, T96-0072
Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery
Phase: Phase I
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: CDR0000068934 (10M-00-4), LAC-USC-10M004, MDX-MDXCTLA4-03, NCI-4210, 4210, NCT00025181
Start Over